Synthetic approach to designed chemical structures

Abstract

This invention relates to the chemical design and production of peptides, peptide structure and three dimensional conformation was assessed using NMR, circular dichroisin and pulsed field gradient NMR. In addition, this invention relates to peptides produced by these methods and to methods for using the peptides.

1 - 20 . (canceled) 
     
     
         21 . A water soluble peptide selected from the group consisting of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:12 SEQ ID NO:13 SEQ ID NO:14 SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18 SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23 SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27 SEQ ID NO:28, SEQ ID NO:29, and SEQ ID NO:30. 
     
     
         22 - 32 . (canceled) 
     
     
         33 . The peptide of  claim 21  further comprising a pharmaceutically acceptable carrier. 
     
     
         34 . The peptide of  claim 42  wherein said pharmaceutically acceptable carrier is selected from the group consisting of isotonic saline, dimethylsulfoxide, alcohol, phosphate buffered saline, and other balanced salt solutions. 
     
     
         35 . The peptide of  claim 21  conjugated to a protein carrier. 
     
     
         36 . The peptide of  claim 35  wherein said protein carrier is selected from the group consisting of keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), and ovalbumin. 
     
     
         37 . A method for treating a bacteria infection or endotoxic shock comprising administering to a mammal an amount of a pharmaceutical composition effective to inhibit the bacterial infection or neutralize endotoxin, wherein the pharmaceutical composition comprises the water soluble peptide of  claim 21  and a pharmaceutically acceptable carrier. 
     
     
         38 . A method for inhibiting TNF-α levels in a mammal comprising administering a therapeutically effective amount of a pharmaceutical composition comprising the water soluble peptide of  claim 21  and a pharmaceutically acceptable carrier. 
     
     
         39 . A method for inhibiting endothelial cell proliferation comprising administering to a mammal an effective amount of a composition comprising the water soluble peptide of  claim 21 . 
     
     
         40 . A method for promoting inter-cellular adhesion molecule expression comprising administering to a mammal an effective amount of a composition comprising the water soluble peptide of  claim 21 . 
     
     
         41 . A method for inhibiting angiogenesis in a cell culture, the method comprising contacting cells with an effective amount of a composition comprising the water soluble peptide of  claim 21 . 
     
     
         42 . A method for inhibiting angiogenesis in a mammal, the method comprising administering to the mammal an effective amount of a composition comprising the water soluble peptide of  claim 21  and a pharmaceutically acceptable carrier. 
     
     
         43 . A method for inhibiting tumorigenesis in a mammal, the method comprising administering to the mammal an effective amount of a composition comprising the water soluble peptide of  claim 21  and a pharmaceutically acceptable carrier. 
     
     
         44 . A method for inhibiting bacterial infection or endotoxic shock in a cell culture, the method comprising contacting cells with an effective amount of a composition comprising a the water soluble peptide of  claim 21 . 
     
     
         45 . A method for inhibiting TNF-α levels in a cell culture, the method comprising contacting cells with an effective amount of a composition comprising a the water soluble peptide of  claim 21 . 
     
     
         46 . A method for inhibiting endothelial cell proliferation in a cell culture, the method comprising contracting cells with an effective amount of a composition comprising the water soluble peptide of  claim 21 . 
     
     
         47 . A method for promoting inter-cellular adhesion molecule expression in a cell culture, the method comprising contacting cells with an effective amount of a composition comprising the water soluble peptide of  claim 21 . 
     
     
         48 . A method for inhibiting inter-cellular adhesion molecule expression down regulation in a mammal, the method comprising administering to the mammal an effective amount of a composition comprising the water soluble peptide of  claim 21 . 
     
     
         49 . A method for inhibiting inter-cellular adhesion molecule expression down regulation in a cell culture, the method comprising contacting cells with an effective amount of a composition comprising the water soluble peptide of  claim 21 . 
     
     
         50 . A method for inhibiting leukocyte/endothelial cell adhesion in a cell culture, the
 method comprising contacting cells with an effective amount of a composition comprising a the water soluble peptide of  claim 21 .   
     
     
         51 . A method of increasing leukocyte cell infiltration in a mammal, the method comprising administering to the mammal an effective amount of a composition comprising a the water soluble peptide of  claim 21 .